Search for in this collection

Subscribe to this collection to receive daily e-mail notification of new additions

Preview	Issue Date	Title	Author(s)
	28-Jul-2026	IRF4 AND SERBP1 EXPRESSION ARE ASSOCIATED WITH POOR RESPONSES TO GUADECITABINE (SGI-110) THERAPY IN PERIPHERAL T CELL LYMPHOMA.	Behrouzfar K.; Abeyakoon C.; Waltham M.; Dorwal P.; Maher B.; Sabouri-Thompson Z.; Scull K.; Brasacchio D.; Gasiorowski R.; Shortt J. ; Yeh P.
	28-Jul-2026	EVALUATION OF PET-CT METRICS AND PHARMACOKINETICS IN ADULTS RECEIVING TISLELIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: ANCILLARY ANALYSES OF LYSA PHASE 2 TIRHOL STUDY BGB-A317-210.	Ghesquieres H.; Bouabdallah K.; Kanoun S.; Andre M.; Quittet P.; Borel C.; Bastard A.S.; Gilbertson M. ; Le Bras F.; Thieblemont C.; Moisdon B.D.; Touati M.; Feugier P.; Renaud L.; Morineau N.; Gastinne T.; Chaillol I.; Ramchandren R.; Shah H.; Modi D.; Allewelt H.; Fustier P.; Liu X.; Zhang J.; Delarue R.; Morschhauser F.; Rossi C.
	28-Jul-2026	PROPOSED DEFINITION FOR 'PRIMARY REFRACTORY' DISEASE IN NODAL PERIPHERAL T-CELL LYMPHOMA: AN AUSTRALASIAN-CANADIAN COLLABORATIVE STUDY.	Abeyakoon C.; Wellard C.; Chung E.; Hodgson D.; Rodin D.; Prica A.; Aoki T.; Vijenthira A.; Opat S. ; Wood E.; McQuilten Z. ; Hawkes E.; Crump M.; Gregory G. ; Kuruvilla J.
	28-Jul-2026	COMBINATION TREATMENT WITH NOVEL BCL2 INHIBITOR SONROTOCLAX (BGB-11417) AND ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R MCL): RESULTS FROM A PHASE 1/1B STUDY.	Soumerai J.; Tam C.S.; Lasica M.; Hoffmann M.; Sanz R.G.; Schetelig J.; Munir T.; Weinkove R.; Browett P.; Barca E.G.; Mayer L.M.; Bernardelli A.; Hou J.-Z.; Cordoba R.; Wu B.; Man G.; Fang Y.; Patel S.; Vezan R.; Opat S.
	28-Jul-2026	IMMUNOHISTOCHEMICAL PRACTICE IN THE DIAGNOSIS OF DIFFUSE LARGE B-CELL LYMPHOMA IN AUSTRALIA.	Ganeshalingam V.; Wellard C.; Chung E.; Bew A.; Bosco A.; Cheah C.Y.; Cushion T.; Fox E.; Hawkes E.; Hui I.; Martynchyk A.; McHenry J.; Opat S. ; Salvaris R.; Waters N.; Wight J.
	28-Jul-2026	TRIAL IN PROGRESS: QUINTESSENTIAL-2-A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VERSUS STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) EXPOSED TO LENALIDOMIDE.	Lebel E.; Abdulgawad A.; Bramanti S.; Garate G.; Ho P.J.; Keranen M.; Cohen Y.; Vase M.O.; Khot A.; Kristensen I.; Leblanc R.; Lee C.; Legiec W.; Magen H.; Mateos M.-V.; Oh D.; Pour L.; Schutz N.; Spyridonidis A.; Weisel K.C.; Zaucha J.M.; Larson S.M.; Varshavsky-Yanovsky A.N.; Grazioli K.; Basudhar D.; Hu H.; Meng Y.; Eldjerou L.; Bal S.; Harrison S.; Popat R.; Raab M.-S.; Rodriguez-Otero P.
	28-Jul-2026	TOTAL METABOLIC TUMOR VOLUME AND CIRCULATING TUMOR DNA AS EARLY PROGNOSTIC FACTORS IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM THE PHASE 3 STARGLO TRIAL.	Townsend W.; Belousov A.; Abramson J.S.; Ku M.; Huang H.; Fox C.P.; Zhang H.-L.; Yoon D.H.; Kim W.; Ghesquieres H.; Herbaux C.; Zhang Q.-Y.; Abdulhaq H.; Jemaa S.; Mulvihill E.; Kallemeijn M.J.; Kesavan M.; Lundberg L.; Bottos A.; Gregory G.P.
	28-Jul-2026	MAINTENANCE OF HEALTH-RELATED QUALITY OF LIFE WITH VENETOCLAX-OBINUTUZUMAB VS CHEMOIMMUNOTHERAPY IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA FROM THE PHASE 3 CRISTALLO TRIAL.	Morschhauser F.; Laurenti L.; Ferrant E.; Montero L.F.C.; Mulligan S.; Harrup R.; Opat S. ; Ibatici A.; Marasca R.; Sportoletti P.; Singh A.; Jin H.Y.; Thadani-Mulero M.; Breuleux M.; Egginton A.; Trask P.; Sharman J.P.
	28-Jul-2026	RESELECT2: A TRIAL EVALUATING ELTROMBOPAG AND RUXOLITINIB FOR THE TREATMENT OF POOR GRAFT FUNCTION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION AND RELAPSED/REFRACTORY SEVERE APLASTIC ANAEMIA.	North D.; Prabahran A.; Asif Ali Shah S.; Koye D.; Braat S.; Klass J.; Rivalland A.; Purtill D.; Belbachir S.; Davis J.; Chee L.; Koldej R.; Ritchie D.
	28-Jul-2026	ERIC REAL-WORLD RETROSPECTIVE ANALYSIS OF OUTCOMES IN CLL PATIENTS TREATED WITH CHEMOTHERAPY-FREE FRONTLINE TARGETED THERAPIES DEMONSTRATES THE IMPACT OF TP53 DISRUPTION IN THE ERA OF NOVEL THERAPY.	Iyengar S.; Chan L.Y.; El-Sharkawi D.; Talimtzi P.; Abburu S.; Adhikari B.; Adlaon A.; Alhuraiji A.; Alshemmari S.; Anderson M.; Angelopoulou M.; Arguello-Tomas M.; Arrais-Rodrigues C.; Marszak F.B.; Barrett A.; Benetatos L.; Blommers R.; Cano A.M.; Chang A.; Chatzicharisi E.; Chatzidimitriou A.; Chatzileontiadou S.; Chung E.; Coscia M.; Maull M.C.; Cutting G.; Davis Z.; De Falco F.; Dimou M.; Doubek M.; Efstathopoulou M.; Sola B.E.; Eyre T.A.; Favrin G.; Fernandez-Rodriguez C.; Forconi F.; Gaidano G.; Garcia Vela J.A.; Gimeno E.; Gohil S.; Gonzalez Gascon Y Marin I.T.; Habib S.; Herishanu Y.; Hatzimichael E.; Joyce K.; Kalicinska E.; Kazmi S.; Kittai A.; Koumpis A.-E.; Kyriakou I.; Lee D.; Levin M.-D.; MacHairas A.; Malcikova J.; Marr H.; Martinez-Calle N.; Martini F.; McKeague S.; Minga E.; Moia R.; Morawska M.; Murru R.; Konstantinou I.; Nath U.K.; Neoh C.; Nicolosi M.; De Oliveira A.C.; Opat S. ; Ortiz Pareja M.; Pangalis G.; Sotirios P.; Pappa V.; Patten P.; Pfister V.; Popov V.M.; Poynton E.; Puiggros A.; Riches J.; Saheed F.; Saeed J.; Sale B.; Sanna A.; Scarfo L.; Serafin A.; Pareja A.S.; Skerget M.; Souto Filho J.T.; Sportoletti P.; Stavrogianni N.; Tadmor T.; Trentin L.; Varettoni M.; Vassilakopoulos T.; Vitale C.; Visentin A.; Wasik-Szczepanek E.; Wehmeyer G.; Wellard C.; Williams S.; Dearden C.; Stamatopoulos K.; Ghia P.; Pavlova S.; Chatzikonstantinou T.
	28-Jul-2026	MAPPING THE METHODOLOGY & ATTRIBUTES OF GLOBAL LYMPHOMA REGISTRIES: A LYMPHOMA REGISTRY ALLIANCE (LYRA) INITIATIVE.	Chung E.; Bishton M.; Cherblanc F.; Claushuis T.A.M.; Chamuleau M.; El-Galaly T.; Enerstvedt L.; Federico M.; Ghesquieres H.; Hess G.; Huang T.-C.; Johannesen T.; Kryachok I.; McQuilten Z. ; Ohler A.; Pauc A.; Shokun N.; Smedby K.E.; Stepanishyna Y.; Sykorova A.; Tomuleasa C.; Trneny M.; Tuan Y.-H.; Wood E.; Hawkes E.
	28-Jul-2026	UPDATED SAFETY AND EFFICACY OF ALL-ORAL SONROTOCLAX + ZANUBRUTINIB IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL), INCLUDING PATIENTS WITH DEL(17P)/TP53.	Opat S. ; Tam C.S.; Anderson M.; Tedeschi A.; Verner E.; Lasica M.; Arbelaez A.; Stilgenbauer S.; Browett P.; Leitch S.; Barca E.G.; Shadman M.; Hou J.-Z.; Eradat H.; Westerman D.; Wu B.; Man G.; Fang Y.; Patel S.; Vezan R.; Cheah C.Y.
	29-Jul-2026	RESULTS FROM THE PHASE 1 MONOTHERAPY DOSE ESCALATION OF APL-4098, AN ORAL GCN2 INHIBITOR, IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML) AND MYELODYSPLASTIC SYNDROMES (MDS)/AML PATIENTS.	Fleming S.; Tan S.Y.; Mokoonlall M.; McQuillan A.; Yeh P.; Chuah H.; Amofa R.; Taussig D.; Green L.; Beerahee M.; Hamilton B.; Clemo N.; Aggarwal S.; Dillon R.
	29-Jul-2026	FINAL RESULTS FROM ASSURE: A PHASE 3B STUDY OF THE SAFETY AND EFFICACY OF ACALABRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA.	Opat S. ; Fogliatto L.; Samoilova O.; Nikitin E.; Kuss B.; Aranha M.; Jujjavarapu S.; De La Serna J.; Hart J.; Banerji V.; Tran H.T.T.; Novikova M.; Dartigeas C.; Eom K.-S.; Merli M.; Deacon E.; Munley J.; Wargo S.; Hermann R.; Awan F.; Niemann C.
	29-Jul-2026	FIRST-LINE TREATMENT OF CLL/SLL WITH THE ALL-ORAL COMBINATION OF SONROTOCLAX AND ZANUBRUTINIB ACHIEVES UNDETECTABLE MINIMAL RESIDUAL DISEASE RATES OF >90%, INCLUDING IN PATIENTS WITH DEL(17P)/TP53.	Cheah C.Y.; Opat S. ; Lasica M.; Browett P.; Anderson M.; Verner E.; Ma S.; Weinkove R.; Hoffmann M.; Soumerai J.; Shadman M.; Munir T.; Leitch S.; Cordoba R.; Westerman D.; Ghia P.; Wu B.; Man G.; Fang Y.; Patel S.; Vezan R.; Tam C.S.
	29-Jul-2026	THERAPEUTIC SILENCING OF TMPRSS6 ATTENUATES IRON-DRIVEN INFLAMMASOME ACTIVATION AND DELAYS DISEASE PROGRESSION IN MDS MICE.	Vadolas J. ; Vilcassim S.; Pholngam N.; Thubthed R.; Nualkaew T.; Svasti S.; Chaichompoo P.; Kysenius K.; Crouch P.; Martinez A.; Schaeper U.; Grigoriadis G.
	29-Jul-2026	SUBSEQUENT THERAPIES AND TIME TO SECOND PROGRESSION-FREE SURVIVAL EVENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA PREVIOUSLY TREATED WITH ZANUBRUTINIB OR BENDAMUSTINE-RITUXIMAB.	Tam C.S.; Kahl B.; Munir T.; Robak T.; Brown J.R.; Ghia P.; Opat S. ; Walker P. ; Lasica M.; Flinn I.W.; Jurczak W.; Shen J.; Lefebure M.; Hirata J.; Shadman M.
	29-Jul-2026	NO EVIDENCE OF QTC INTERVAL PROLONGATION WITH THE MENIN INHIBITOR BLEXIMENIB WHEN GIVEN AS MONOTHERAPY OR IN COMBINATION WITH AML-DIRECTED THERAPIES FOR KMT2A OR NPM1 ALTERED AML.	Abdul-Hay M.; Abedin S.; Aldoss I.; Pierola A.A.; Dominguez J.M.A.; Daskalakis N.; Dohner H.; D'souza A.; Dunavin N.; Reyner J.E.; Exum M.; Fathi A.; Fedele P. ; Ferrante L.; Garciaz S.; Diaz A.G.; Gyan E.; Haddish-Berhane N.; Jabbour E.; Jentzsch M.; Konopleva M.; Kronke J.; Kumar A.; Luo D.; Loefgren C.; Lomas O.; Mancini V.; Mantzaris I.; Mitselos A.; Morillo D.; Ng T.F.; Norata M.; O'nions J.; Packman K.; Papayannidis C.; Philippar U.; Psarros G.; Recher C.; Rollig C.; Sakey N.; Salamero O.; Sauer T.; Searle E.; Nagarajahastri P.; Stone R.; Tan P.; Sun T.; Tucker T.; Vaughan L.; Vega G.; Vyas P.; Wei A.H.; Hutter-Kronke M.L.
	29-Jul-2026	FRONTLINE ASCIMINIB FOR CHRONIC PHASE CML: LONG TERM SAFETY AND EFFICACY IN THE ALLG CM13 ASCEND TRIAL.	Yeung D.; Shanmuganathan N.; Shortt J. ; Yong A.; Chee L.; Reynolds J.; Viiala N.; Cunningham I.; Ross D. ; D'souza A.; Wright M.; Harrup R.; Forsyth C.; Filshie R.; Lane S.; Browett P.; Grove C.; Gazdar S.G.; Walia M.; Branford S.; Grigg A.; Hughes T.
	29-Jul-2026	VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: FINAL RESULTS OF THE RANDOMIZED CLL14 STUDY.	Fischer K.; Al-Sawaf O.; Robrecht S.; Giza A.; Zhang C.; Fink A.-M.; Schneider C.; Kreuzer K.-A.; Chagorova T.; Sivcheva L.; Samoilova O.; Opat S. ; Niemann C.; Aurer I.; Bogdanov L.; Schwarer A.; Poulsen C.B.; Butler A.; Pueyo J.L.; Owen C.; Spasov E.A.; Wendtner C.; Wrisch A.; Murray B.; Breuleux M.; Jiang Y.; Jin H.Y.; Tausch E.; Schilhabel A.; Ritgen M.; Stilgenbauer S.; Eichhorst B.; Hallek M.